Making Individualized Decisions in the Midst of Uncertainties: The Case of Prostate Cancer and Biochemical Recurrence

Published on Dec 1, 2013in European Urology17.947
· DOI :10.1016/J.EURURO.2013.07.001
Ronald C. Chen32
Estimated H-index: 32
(UNC: University of North Carolina at Chapel Hill)
Sources
Abstract
The decision about whether to pursue aggressive treatment is one of the most common decisions in all of oncology, and it always includes uncertainties, patient preferences, and priorities. Often patients and physicians must make this decisionwithout guidance from randomized trial data. Even when trials have been conducted and demonstrated an overall benefit from an aggressive treatment, patients and physicians still must decide whether a benefit is likely at an individual level based on a patient’s comorbid illnesses, life expectancy, and other medical or personal considerations. Consequently, the decision-making process for a prostate cancer (PCa) patient at the time of biochemical recurrence (BCR) is really no different than the decision-making process for primary PCa treatment and, in fact, is not that different from the process for any other cancer. In the current issue of European Urology, Punnen and colleagues performed a beautiful systematic review of the literature on the management options for BCR in PCa [1], a common clinical situation faced by hundreds of thousands of men worldwide each year. What the authors found were many predictive models aimed at distinguishing patients who have local versus distant recurrence—an important distinction because the former is curable with aggressive salvage therapy but the latter is not. Few published models, however, have been externally validated, and many have only modest accuracy. Other studies have reported on factors associated with clinical progression and death in patients who develop a BCR, factors associated with achieving a prostate-specific antigen (PSA) response from salvage radiation therapy (RT) after prostatectomy, and efficacy and morbidity from salvage treatments in various
📖 Papers frequently viewed together
11 Citations
2 Citations
References10
Newest
#1Sanoj Punnen (UCSF: University of California, San Francisco)H-Index: 10
#1Sanoj Punnen (UCSF: University of California, San Francisco)H-Index: 16
Last. Stephen J. Freedland (Duke University)H-Index: 96
view all 8 authors...
Context: Despite excellent cancer control with the treatment of localized prostate cancer (PCa), some men will experience a recurrence of disease. The optimal management of recurrent disease remains uncertain. Objective: To systematically review recent literature regarding management of biochemical recurrence after primary treatment for localized PCa.
107 CitationsSource
#1Nathan C. SheetsH-Index: 14
#2Laura H. HendrixH-Index: 11
Last. Ronald C. ChenH-Index: 32
view all 4 authors...
BACKGROUND For patients with adverse pathologic factors (positive surgical margins, extracapsular extension, or seminal vesicle invasion) on prostatectomy pathology, the use and timing of postsurgical treatments are controversial. The goal of the current study was to examine patterns of care in patients with a pathologic indication for postprostatectomy radiotherapy (RT) using the Surveillance, Epidemiology, and End Results (SEER)-Medicare–linked database. METHODS A total of 3460 men treated wit...
37 CitationsSource
#1Michel BollaH-Index: 56
#2Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 26
Last. Laurence Collette (European Organisation for Research and Treatment of Cancer)H-Index: 86
view all 19 authors...
Summary Background We report the long-term results of a trial of immediate postoperative irradiation versus a wait-and-see policy in patients with prostate cancer extending beyond the prostate, to confirm whether previously reported progression-free survival was sustained. Methods This randomised, phase 3, controlled trial recruited patients aged 75 years or younger with untreated cT0–3 prostate cancer (WHO performance status 0 or 1) from 37 institutions across Europe. Eligible patients were ran...
589 CitationsSource
#1Andrew J. Stephenson (Cleveland Clinic)H-Index: 57
#2Michel BollaH-Index: 56
Last. Anthony L. Zietman (Harvard University)H-Index: 80
view all 8 authors...
Context: Approximately 15–25% of men who undergo radical prostatectomy for localized prostate cancer (PCa) will experience recurrence of their cancer; men with poorly differentiated cancer, non–organ-confined disease, and positive surgical margins are at the highest risk. Objective: Review accumulating evidence indicating that postoperative radiotherapy (RT) to the prostate bed favorably influences the course of disease in men with adverse pathologic features. Evidence acquisition: Three phase 3...
95 CitationsSource
#1Karen E. Hoffman (University of Texas MD Anderson Cancer Center)H-Index: 37
#2Paul L. Nguyen (Harvard University)H-Index: 68
Last. Anthony V. D'Amico (Harvard University)H-Index: 93
view all 8 authors...
Purpose: The EORTC 22911 and the SWOG 8794 studies, presented in 2004 and 2005, showed that adjuvant radiation therapy after prostatectomy improved biochemical disease-free survival in men with adverse pathological features. In this study we evaluated the use of post-prostatectomy radiation therapy following the presentation of these results, and the impact of margin involvement, pathological tumor stage, Gleason score and sociodemographic factors on post-prostatectomy radiation therapy recommen...
73 CitationsSource
#1Thomas WiegelH-Index: 50
#2Dirk BottkeH-Index: 14
Last. Kurt MillerH-Index: 73
view all 20 authors...
Purpose Local failure after radical prostatectomy (RP) is common in patients with cancer extending beyond the capsule. Two randomized trials demonstrated an advantage for adjuvant radiotherapy (RT) compared with a wait-and-see policy. We conducted a randomized, controlled clinical trial to compare RP followed by immediate RT with RP alone for patients with pT3 prostate cancer and an undetectable prostate-specific antigen (PSA) level after RP. Methods After RP, 192 men were randomly assigned to a...
692 CitationsSource
#1Ian M. Thompson (University of Texas Health Science Center at San Antonio)H-Index: 110
#2Catherine M. Tangen (Fred Hutchinson Cancer Research Center)H-Index: 63
Last. E. David Crawford (University of Colorado Hospital)H-Index: 100
view all 12 authors...
Purpose: Extraprostatic disease will be manifest in a third of men after radical prostatectomy. We present the long-term followup of a randomized clinical trial of radiotherapy to reduce the risk of subsequent metastatic disease and death.Materials and Methods: A total of 431 men with pT3N0M0 prostate cancer were randomized to 60 to 64 Gy adjuvant radiotherapy or observation. The primary study end point was metastasis-free survival.Results: Of 425 eligible men 211 were randomized to observation ...
984 CitationsSource
#1Bruce J. Trock (Johns Hopkins University)H-Index: 86
#2Misop Han (AMA: American Medical Association)H-Index: 61
Last. Patrick C. WalshH-Index: 151
view all 7 authors...
Nearly 60 000 men (27% of newly diagnosed cases) will have undergone radical prostatectomy in 2007.1 Although surgery provides excellent cancer control, approximately 15% to 40% of these men will experience cancer recurrence within 5 years,2,3 usually manifested only by elevated prostate-specific antigen (PSA) level. It is currently difficult to determine whether increasing serum PSA level after surgery represents an isolated recurrence at the surgical site or occult metastases that cannot be de...
531 CitationsSource
#1Carol M. Moinpour (Fred Hutchinson Cancer Research Center)H-Index: 53
#2Katherine A. Hayden (Fred Hutchinson Cancer Research Center)H-Index: 3
Last. E. David Crawford (Fred Hutchinson Cancer Research Center)H-Index: 1
view all 11 authors...
Purpose To compare short- and long-term effects of adjuvant treatment versus observation after surgery on health-related quality of life (HRQL) of prostate cancer patients. Patients and Methods The Southwest Oncology Group (SWOG) intergroup trial compared radical prostatectomy (RP) plus observation versus RP plus adjuvant radiation therapy (RT). Two-hundred seventeen of 425 therapeutic trial patients were eligible and registered to the HRQL study. Patients completed the SWOG Quality of Life Ques...
137 CitationsSource
#1Andrew J. Stephenson (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 57
#2Shahrokh F. Shariat (UTSW: University of Texas Southwestern Medical Center)H-Index: 132
Last. Kevin M. Slawin (BCM: Baylor College of Medicine)H-Index: 65
view all 16 authors...
Context Salvage radiotherapy may potentially cure patients with disease recurrence after radical prostatectomy, but previous evidence has suggested that it is ineffective in patients at the highest risk of metastatic disease progression. Objective To delineate patients who may benefit from salvage radiotherapy for prostate cancer recurrence by identifying variables associated with a durable response. Design, Setting, and Patients Retrospective review of a cohort of 501 patients at 5 US academic ...
572 CitationsSource
Cited By5
Newest
#1Jane M. Lange (Fred Hutchinson Cancer Research Center)H-Index: 16
#2Bruce J. TrockH-Index: 86
Last. Ruth Etzioni (Fred Hutchinson Cancer Research Center)H-Index: 65
view all 4 authors...
Background. Of the 50,000 men in the US who elect for radical prostatectomy for prostate cancer, 24% to 40% will have a prostate-specific antigen (PSA) recurrence (PSA-R) within 10 years. Deciding whether to administer salvage therapy (ST) at PSA-R presents challenges, as treatment reduces the risk of progression to clinical metastasis but incurs unnecessary side effects should the man die before metastasis. We have developed a new harm–benefit framework using a clinical cohort to inform shared ...
5 CitationsSource
#1Silvia Sommariva (Bocconi University)H-Index: 8
#2Rosanna Tarricone (Bocconi University)H-Index: 25
Last. Francesco Montorsi (UniSR: Vita-Salute San Raffaele University)H-Index: 138
view all 5 authors...
Abstract Context The process of care for patients with prostate cancer is subject to different degrees of uncertainty. Patients and clinicians could, therefore, greatly benefit from improved prognostic instruments. One emerging tool is the cell cycle progression (CCP) score. Objective This systematic review assesses evidence on the value of the CCP instrument in prostate cancer treatment by reviewing current publications and integrating the results via a meta-analysis. Evidence acquisition We pe...
44 CitationsSource
#1Jing Xia (Fred Hutchinson Cancer Research Center)H-Index: 9
#2Bruce J. Trock (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 86
Last. Ruth Etzioni (Fred Hutchinson Cancer Research Center)H-Index: 65
view all 8 authors...
Purpose: Prostate-specific antigen recurrence (PSA-R) after radical prostatectomy (RP) can occur years before metastasis. This study estimates the chance that an untreated PSA-R would not progress to clinical metastasis within the patient9s lifetime, that is, that recurrence is overdetected. Experimental Design: Times from PSA-R to metastasis were estimated from patients with RP treated at Johns Hopkins University (Baltimore, MD) who did not receive salvage treatment ( n = 441) at PSA-R. Times t...
17 CitationsSource
#1Nathan Lawrentschuk (Ludwig Institute for Cancer Research)H-Index: 58
3 CitationsSource
#1Sanoj Punnen (UCSF: University of California, San Francisco)H-Index: 10
#1Sanoj Punnen (UCSF: University of California, San Francisco)H-Index: 16
Last. Stephen J. Freedland (Duke University)H-Index: 96
view all 3 authors...
[2] Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA2008;299: 2760–9. [3] Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291:1325–32. [4] Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk o...
Source